Skip to main content

Table 2 TS-1 dose modification and compliance of patients with gastric cancer

From: Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment

  n (%)
Received treatment schedule modification 18 (45)
Underwent dose de-escalation 6 (15)
Discontinued TS-1 treatment at study end 31 (77.5)
Reasons for discontinuation  
Completion of TS-1 treatment 14 out of 31 (45)
Toxicity 9 out of 31 (29)
Tumor recurrence 6 out of 31 (19)
Economic factors 2 out of 31 (6)
TS-1 treatment duration (compliance)  
At least 3 months 30 out of 38 (78.9)
At least 6 months 26 out of 35 (74.3)
At least 9 months 18 out of 29 (62.1)
Completed nine full cycles 14 out of 25 (56)
  1. The median TS-1 treatment duration was 226 days (range 7 to 400). TS-1 compliance: the number of patients who discontinued treatment because of toxicity or economic factor subtracted from the number of patients who underwent TS-1 treatment at the given time. Patients who withdrew from TS-1 treatment owing to tumor relapse were excluded in the TS-1 compliance calculation for any given time.